Belite Bio, Inc
BLTE
$183.16
-$9.69-5.03%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 220.08% | 338.58% | 369.99% | 291.62% | 100.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 145.06% | 136.32% | 68.05% | 86.32% | 64.73% |
| Operating Income | -145.06% | -136.32% | -68.05% | -86.32% | -64.73% |
| Income Before Tax | -150.73% | -149.91% | -71.90% | -81.53% | -44.47% |
| Income Tax Expenses | -- | -- | -- | -- | 100.00% |
| Earnings from Continuing Operations | -150.73% | -149.91% | -71.90% | -81.39% | -44.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -150.73% | -149.91% | -71.90% | -81.39% | -44.49% |
| EBIT | -145.06% | -136.32% | -68.05% | -86.32% | -64.73% |
| EBITDA | -145.65% | -136.84% | -68.20% | -86.60% | -64.88% |
| EPS Basic | -117.82% | -130.87% | -59.95% | -67.80% | -30.01% |
| Normalized Basic EPS | -117.74% | -130.77% | -- | -- | -30.07% |
| EPS Diluted | -117.82% | -130.87% | -59.95% | -67.80% | -30.01% |
| Normalized Diluted EPS | -117.74% | -130.77% | -- | -- | -30.07% |
| Average Basic Shares Outstanding | 15.13% | 8.26% | 7.46% | 8.11% | 11.10% |
| Average Diluted Shares Outstanding | 15.13% | 8.26% | 7.46% | 8.11% | 11.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |